

Financial Statements
for the Fiscal Year Ended March 31, 2013
(From Apr. 1, 2012 to Mar. 31, 2013)

Summary of consolidated results

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.

Highlights in Business Results

Increased both in Sales and Profit for the Fiscal Year Ended March 31, 2013

Sales: JPY 49.0 billion, up 4.8% - 9th consecutive year of sales increase (%: compared with previous year)

Sales	[Japan]
	<ul style="list-style-type: none"> -Continued growth in the sales of infusion sets with needleless access port “Planecta” and extension tube sets -Positive sales of hemodialysis blood tubing sets
	[Overseas]
	<ul style="list-style-type: none"> -Positive sales of apheresis kits for OEM customer and blood bags for Southeast Asia -Continued solid sales of safety scalp vein sets for North America

Operating income: JPY 1.5 billion (up 51.5%), Ordinary income: JPY 1.8 billion (up 36.0%),
Net income: JPY 1.2 billion (up 35.5%)

Profit	<ul style="list-style-type: none"> -Increased revenues offsetting impact of increased labor costs in emerging countries -Investment gains under the Equity method and foreign exchange gains
--------	--

Dividend forecast for the Fiscal Year Ended Mar. 2013

-Annual dividend: JPY 8 per share (incl. interim dividend JYP 4 per share)

Consolidated Business Results



Increased both in Sales and Profit

(unit: JPY million)


	Results Apr. - Mar. 2012	Results Apr. - Mar. 2013	Year – over – Year
Sales	46,836	49,068	4.8%
Operating Income	1,052	1,594	51.5%
Ordinary Income	1,382	1,879	36.0%
Net Income	942	1,277	35.5%
Net Income per share	JPY 21.84	JPY 29.41	---

Sales by segment (geographical area)



Apr. – Mar. 2012
 Apr. – Mar. 2013

(unit: JPY million)




Profit by segment (geographical area)



Apr. – Mar. 2012 Apr. – Mar. 2013

(unit: JPY million)



Summary by segment (geographical area)




?: year-over-year



Japan

Sales	39,758 JPY mil.	2.4%
Ordinary Income	1,418 JPY mil.	136.2%

-Continued growth in the sales of infusion sets with needleless access port "Planecta" and extension tube sets



Infusion set with a needleless access port, "PLANECTA"

Infusion set is used for drug administration to a human body. "PLANECTA" is a needleless access port, allowing connections without a needle, which offers minimized infection risk to patients and medical staff by reducing the risk of contamination coming from blood or solution, and preventing needle-stick accidents.



Southeast Asia

Sales	14,497 JPY mil.	18.2%
Ordinary Income	66 JPY mil.	(35.8%)

-Positive sales of apheresis kits for OEM customer, blood bags for Southeast Asia and hemodialysis blood tubing sets for Japan



Hemodialysis blood tubing set

Hemodialysis tubing set is used for circulating blood by hemodialysis machine during dialysis therapy.



China


Sales	3,186 JPY mil.	9.2%
Ordinary Income	45 JPY mil.	(70.9%)

-Continued solid sales of AV fistula needles for Japan and the domestic market

Summary by segment (geographical area)



?: year-over-year



Germany

Sales	2,550 JPY mil.	(8.9%)
Ordinary Income	116 JPY mil.	(47.6%)

-Continued growth in the sales of AV fistula needles for the domestic market was offset by the sales drop of dialysis therapy chairs and foreign exchange conditions



AV Fistula Needle

AV fistula needle is for pulling blood from a patient during a dialysis therapy.



United States

Sales	2,134 JPY mil.	(1.9%)
Ordinary Income	115 JPY mil.	(47.5%)

-Continued solid sales of safety scalp vein sets for North America was offset by the sales drop of AV fistula needles



Safety Scalp Vein set

Safety scalp vein set is an injection needle with tube for infusion and blood sampling. It has a safety function to prevent medical staff from accidental needle sticks.



Others


Sales	1,236 JPY mil.	11.8%
Ordinary Income	72 JPY mil.	(35.5%)

Sales by Business Segment



(unit: JPY million)


Apr. – Mar. 2012 Apr. – Mar. 2013



Selling, General and Admin. Expenses




(unit: JPY million)



(unit: JPY million)

	Apr. - Mar. 2012	Apr. - Mar. 2013	Diff.	Year-over-Year
Labor Cost	5,212	5,275	63	1.2%
Transport	1,309	1,401	92	7.1%
R & D	1,427	1,243	(183)	(12.9%)
Depreciation	458	345	(113)	(24.7%)
Others	3,280	3,578	297	9.1%
Total	11,687	11,844	156	1.3%

Ordinary Income: Compared with the last year



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2014



(unit: JPY million)

	FYE Mar. 2013 Result	FYE Mar. 2014 Forecast	Diff.
Sales	49,068	51,500	5.0%
Operating Income	1,594	2,100	31.7%
Ordinary Income	1,879	2,300	22.4%
Net Profit	1,277	1,400	9.6%
Net profit per share	JYP 29.41	JPY 28.70	---

With the three key words, “Medical Safety”, “Promotion of efficiency in medical care” and “Regenerative Medicine”, JMS is striving to increase profitability by expanding sales of the products which contribute to medical safety and meet the changing market demands, and promoting cost reduction in all areas.

Furthermore, by expanding its product portfolio arising from alliance, as well as by creating added value in products with its own technologies, JMS is promoting its sales activity.

- Commissioned the development of blood flow meter to Pioneer Corporation.

Mar. 21, 2013

- Issuing of new shares by public offering and allocation to a third party.

Feb. 21, 2013

- Launching new product “PEGLOCK”, Gastrostomy feeding tube kit.

Feb. 15, 2013

Gastrostomy feeding tube kit
“PEGLOCK”



- Date shows the press release date.

The Bridge to Good Health Care



JMS will continue its activities for contributing to medical care, with our corporate philosophy “Patient comes first”.

JMS continue to dedicate effort to creating happiness for patients, their families and medical staff in line with its basic principle, **“delivering goods and services for our customer’s satisfaction ”**.

Thank you very much for your patronage and support.